Optimised and rapid pre-clinical screening in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS)

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Mead, Richard J ^a   Bennett, Ellen J ^a   Kennerley, Aneurin J ^b   Sharp, Paul ^a,b   Sunyach, Claire ^c,d   Kasher, Paul ^a   Berwick, Jason ^b   Pettmann, Brigitte ^c,d   Battaglia, Guiseppe ^b   Azzouz, Mimoun ^a   Grierson, Andrew ^a   Shaw, Pamela J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Turing Center for Living Systems CENTURI Aix Marseille University   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TISSUE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; FEMALE; GAIT; HISTOLOGY; INBRED STRAIN; MALE; MOTOR DYSFUNCTION; MOUSE; MUSCLE CELL; MUSCLE MASS; NEUROMUSCULAR SYNAPSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; REPRODUCIBILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE; AMINO ACID SUBSTITUTION; ANIMAL; C57BL MOUSE; ENZYMOLOGY; GENETICS; HINDLIMB; HUMAN; MASS SCREENING; MUSCLE; MUSCLE ATROPHY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

MUS; MUS MUSCULUS;

AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GAIT; HINDLIMB; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLES; MUSCULAR ATROPHY; NEUROMUSCULAR JUNCTION; ORGAN SIZE; REPRODUCIBILITY OF RESULTS; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 80051830113     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023244     Document Type: Article

References (53)

1. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.
2. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, et al. (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185: 232-240.
3. Pun S, Santos AF, Saxena S, Xu L, Caroni P, (2006) Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 9: 408-419.
4. Brooks KJ, Hill MD, Hockings PD, Reid DG, (2004) MRI detects early hindlimb muscle atrophy in Gly93Ala superoxide dismutase-1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosis. NMR Biomed 17: 28-32.
5. Kong J, Xu Z, (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18: 3241-3250.
6. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326-334.
7. Andrus PK, Fleck TJ, Gurney ME, Hall ED, (1998) Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71: 2041-2048.
8. Bendotti C, Tortarolo M, Suchak SK, Calvaresi N, Carvelli L, et al. (2001) Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 79: 737-746.
9. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, et al. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 99: 1604-1609.
10. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105-1116.
11. Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, et al. (1996) Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A 93: 3155-3160.
12. Morrison BM, Gordon JW, Ripps ME, Morrison JH, (1996) Quantitative immunocytochemical analysis of the spinal cord in G86R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol 373: 619-631.
13. Zhang B, Tu P, Abtahian F, Trojanowski JQ, Lee VM, (1997) Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol 139: 1307-1315.
14. Williamson TL, Cleveland DW, (1999) Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 2: 50-56.
15. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, et al. (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 16: 2720-2728.
16. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J, Rene F, et al. (2009) Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One 4: e5390.
17. Frey D, Schneider C, Xu L, Borg J, Spooren W, et al. (2000) Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 20: 2534-2542.
18. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, et al. (2006) Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia. Science 312: 1389-1392.
19. Schnabel J, (2008) Neuroscience: Standard model. Nature 454: 682-685.
20. Benatar M, (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26: 1-13.
21. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9: 4-15.
22. Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loffler JP, et al. (2007) Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler 8: 217-223.
23. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11: 38-45.
24. Chia R, Achilli F, Festing MF, Fisher EM, (2005) The origins and uses of mouse outbred stocks. Nat Genet 37: 1181-1186.
25. Taft RA, Davisson M, Wiles MV, (2006) Know thy mouse. Trends Genet 22: 649-653.
26. Russell W, Burch RL, (1959) The Principles of Humane Experimental Technique London Methuen (reprinted by UFAW).
27. Festing MFW, Overend P, Das RG, Borja MC, Berdoy M, (2002) The Design of Animal Experiments London RSM Press.
28. Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, et al. (2004) Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res 130: 7-15.
29. Vrinten DH, Hamers FF, (2003) 'CatWalk' automated quantitative gait analysis as a novel method to assess mechanical allodynia in the rat; a comparison with von Frey testing. Pain 102: 203-209.
30. Festing MF, (2010) Improving toxicity screening and drug development by using genetically defined strains. Methods Mol Biol 602: 1-21.
31. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, et al. (2005) Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 236: 1-7.
32. Knippenberg S, Thau N, Dengler R, Petri S, (2010) Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Behav Brain Res 213: 82-87.
33. De Bono JP, Adlam D, Paterson DJ, Channon KM, (2006) Novel quantitative phenotypes of exercise training in mouse models. Am J Physiol Regul Integr Comp Physiol 290: R926-934.
34. Goodrick CL, (1975) Life-span and the inheritance of longevity of inbred mice. J Gerontol 30: 257-263.
35. Barneoud P, Lolivier J, Sanger DJ, Scatton B, Moser P, (1997) Quantitative motor assessment in FALS mice: a longitudinal study. Neuroreport 8: 2861-2865.
36. Hayworth CR, Gonzalez-Lima F, (2009) Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience 164: 975-985.
37. Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, et al. (2005) Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32: 43-50.
38. Kennel PF, Finiels F, Revah F, Mallet J, (1996) Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Neuroreport 7: 1427-1431.
39. Amendola J, Verrier B, Roubertoux P, Durand J, (2004) Altered sensorimotor development in a transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 20: 2822-2826.
40. van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, et al. (2008) Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci 28: 10864-10874.
41. Bories C, Amendola J, Lamotte d'Incamps B, Durand J, (2007) Early electrophysiological abnormalities in lumbar motoneurons in a transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 25: 451-459.
42. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, et al. (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci 191: 25-33.
43. Mourelatos Z, Gonatas NK, Stieber A, Gurney ME, Dal Canto MC, (1996) The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc Natl Acad Sci U S A 93: 5472-5477.
44. Miana-Mena FJ, Munoz MJ, Yague G, Mendez M, Moreno M, et al. (2005) Optimal methods to characterize the G93A mouse model of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 6: 55-62.
45. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8 (6): e1000412.
46. Bittner RE, Anderson LV, Burkhardt E, Bashir R, Vafiadaki E, et al. (1999) Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 23: 141-142.
47. Reinholz MM, Merkle CM, Poduslo JF, (1999) Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol 159: 204-216.
48. Kim K, Moore DH, Makriyannis A, Abood ME, (2006) AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542: 100-105.
49. Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, et al. (2007) Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2: e1205.
50. Faul F, Erdfelder E, Lang AG, Buchner A, (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
51. Alves CJ, de Santana LP, Santos AJ, de Oliveira GP, Duobles T, et al. (2011) Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Res 1394: 90-104.
52. Graber DJ, Hickey WF, Harris BT, (2010) Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation 7: 8.
53. Henkel JS, Beers DR, Siklos L, Appel SH, (2006) The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci 31: 427-437.